The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Biosimilars in Pharmaceuticals: Hormone-based therapies for metabolic disorders. Buy the report here.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Hormone-based therapies for metabolic disorders is a key innovation area in biosimilars
Hormone therapy, also called endocrine therapy, is the use of hormones as a therapeutic agent. Glucagon and insulin are the major hormonal therapies widely used for the treatment of various metabolic diseases such as type 2 diabetes mellitus, obesity, and hypoglycaemia.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 120+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of hormone-based therapies for metabolic disorders.
Key players in hormone-based therapies for metabolic disorders – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to hormone-based therapies for metabolic disorders
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Novo Nordisk Foundation||1163||Unlock company profile|
|Hanmi Science||698||Unlock company profile|
|Eli Lilly and||646||Unlock company profile|
|Zealand Pharma||637||Unlock company profile|
|Merck & Co||317||Unlock company profile|
|AstraZeneca||218||Unlock company profile|
|Moderna||178||Unlock company profile|
|GSK||169||Unlock company profile|
|Ipsen||142||Unlock company profile|
|Sanofi||120||Unlock company profile|
|C. H. Boehringer Sohn||118||Unlock company profile|
|Amunix Operating||111||Unlock company profile|
|OPKO Health||102||Unlock company profile|
|Biocon||99||Unlock company profile|
|Alkermes||81||Unlock company profile|
|Intarcia Therapeutics||77||Unlock company profile|
|Mederis Diabetes||75||Unlock company profile|
|Jiangsu Hengrui Medicine||65||Unlock company profile|
|Pfizer||65||Unlock company profile|
|Gmax Biopharm||61||Unlock company profile|
|IP Group||53||Unlock company profile|
|Takeda Pharmaceutical||52||Unlock company profile|
|Amgen||49||Unlock company profile|
|BioAtla||46||Unlock company profile|
|F. Hoffmann-La Roche||46||Unlock company profile|
|MannKind||46||Unlock company profile|
|Akston Biosciences||41||Unlock company profile|
|Teva Pharmaceutical Industries||38||Unlock company profile|
|Jiangsu Haosen Pharmaceutical Group||37||Unlock company profile|
|Vectus Biosystems||37||Unlock company profile|
|Adocia||36||Unlock company profile|
|Zydus Lifesciences||36||Unlock company profile|
|PhaseBio Pharmaceuticals||33||Unlock company profile|
|Ferring Holding||33||Unlock company profile|
|CBL Patras||30||Unlock company profile|
|Ambrx Biopharma||29||Unlock company profile|
|Rubius Therapeutics||28||Unlock company profile|
|Life Sciences Research Partners VZW||26||Unlock company profile|
|ImCyse||25||Unlock company profile|
|Orgenesis||25||Unlock company profile|
|Ascendis Pharma||25||Unlock company profile|
|BrightGene Bio-Medical Technology||25||Unlock company profile|
|Shanghai Benemae Pharmaceutical||24||Unlock company profile|
|Boston Scientific||24||Unlock company profile|
|Sun Pharmaceutical Industries||23||Unlock company profile|
|Tel Hashomer Medical Research Infrastructure and Services||23||Unlock company profile|
|AngioChem||23||Unlock company profile|
|Genexine||22||Unlock company profile|
|D&D Pharmatech||21||Unlock company profile|
|HEC Pharm Group||21||Unlock company profile|
Source: GlobalData Patent Analytics
Novo Nordisk is the top pharmaceutical company in metabolic diseases and the leading patent filer in hormone-based therapies. It has 20+ approved drugs and 40+ drugs under development for metabolic disorders. Hanmi Science and Eli Lilly are the other key patent filers in hormone-based therapies for metabolic disorders.
In terms of application diversity, Adocia is the top company, followed by Tel Hashomer Medical Research Infrastructure and Services and Orgenesis. By means of geographic reach, Rubius Therapeutics held the top position. Teva Pharmaceutical Industries and C. H. Boehringer Sohn stood in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.